<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523025</url>
  </required_header>
  <id_info>
    <org_study_id>T197/2020</org_study_id>
    <nct_id>NCT04523025</nct_id>
  </id_info>
  <brief_title>Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)</brief_title>
  <acronym>NorCys-NLR</acronym>
  <official_title>Nordic Cystectomy Study I - Prospective Validation of Neutrophil/Lymphocyte Ratio as Predictor of Bladder Cancer Survival Risk After Radical Cystectomy for Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Urothelial Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Around 7200 cases of Muscle Invasive Bladder Cancer are diagnosed annually in the Nordic&#xD;
      countries combined. Muscle Invasive Bladder Cancer is an aggressive disease and it is linked&#xD;
      with high mortality rates. The golden standard of treatment is radical cystectomy (RC) (the&#xD;
      surgical removal of the bladder) and radical removal of lymph nodes in the pelvis. In&#xD;
      addition to surgical treatment, and especially in cases where the tumour invades tissues&#xD;
      surrounding the bladder or lymph nodes, chemotherapy is recommended. Chemotherapy can be&#xD;
      administered before or after surgery, in a neoadjuvant (NAC) or adjuvant setting (AC).&#xD;
      Although most patients recover well from surgery, there are significant risks regarding&#xD;
      radical cystectomy. The greatest challenges in planning the treatment are making individual&#xD;
      risk assessments and prognosis for the treated patients. Neoadjuvant chemotherapy is also&#xD;
      insufficiently used and it is hard to predict how the tumour responds to chemotherapy.&#xD;
&#xD;
      The purpose of this study is to collect prospective clinical data on radical cystectomy&#xD;
      -patients in co-operation with other Nordic countries: Sweden, Denmark, Iceland and Norway.&#xD;
      The collected data is used to validate existing prediction tools and discover novel tools for&#xD;
      prediction of morbidity related to RC and prediction of oncological outcome after RC. The&#xD;
      study is divided into three sub-studies. The second sub-study is on the preoperative&#xD;
      neutrophil-lymphocyte ratio (NLR). Some studies suggest that NLR might be a predictor of&#xD;
      oncological outcome of BC after RC. In addition, NLR has been suggested to correlate with NAC&#xD;
      response and outcome after NAC and RC. The used cut-off value for NLR has varied between&#xD;
      2.26-3.0.&#xD;
&#xD;
      Patients will be allocated into two groups: low NLR ratio (NLR&lt;3), and high NLR ratio&#xD;
      (NLR≥3). The lab test will be retrieved before RC at the time of routine clinical laboratory&#xD;
      testing for all patients and also before the initiation of NAC for patients planned to have&#xD;
      chemotherapy. The primary end-point is bladder-cancer specific survival and, and secondary&#xD;
      endpoints include progression-free, and overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Bladder-cancer specific survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Low NLR-ratio</arm_group_label>
    <description>Patients with low NLR ratio (NLR&lt;3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High NLR-ratio</arm_group_label>
    <description>Patients with high NLR ratio (NLR≥3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NLR-ratio</intervention_name>
    <description>The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation</description>
    <arm_group_label>High NLR-ratio</arm_group_label>
    <arm_group_label>Low NLR-ratio</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with muscle-invasive bladder cancer undergoing radical cystectomy -surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed urinary BC planned to be treated with RC with or without&#xD;
             neoadjuvant chemotherapy.&#xD;
&#xD;
          2. Histologically confirmed urinary BC planned to be treated with palliative cystectomy&#xD;
             2) Signed informed consent 3) Patient age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. RC for other reasons than BC&#xD;
&#xD;
          2. Other forms of surgical treatment of BC than RC (e.g. bladder resection).&#xD;
&#xD;
          3. Patient unwillingness to participate in the study for any reason (i.e. lack of signed&#xD;
             consent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Boström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Otto Ettala, MD, PhD</last_name>
    <phone>23130280</phone>
    <phone_ext>+358</phone_ext>
    <email>otto.ettala@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilkka Nikulainen, MD</last_name>
    <phone>23137928</phone>
    <phone_ext>+358</phone_ext>
    <email>ilkka.nikulainen@tyks.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Turku, Hospital Distric of Southwest Finland</name>
      <address>
        <city>Turku</city>
        <state>Southwest Finland</state>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Ettala, MD, PhD</last_name>
      <phone>23130280</phone>
      <phone_ext>+358</phone_ext>
      <email>otto.ettala@tyks.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

